ワクチン接種したニワトリのニューカッスル病に対する免疫および腸内組織病理学的改善のためのミコトキシン結合剤
Erma Safitri1, Hery Purnobasuki2, Tita Damayanti Lestari1
1Department of Veterinary Science, Division of Veterinary Reproduction, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, East Java, 60115, Indonesia.
F1000Research
|August 21, 2025
まとめ
ミコトキシン結合剤は,ニコニコ病のワクチン接種後にブローカーの健康と免疫を改善しました. 毒素結合剤の1. 6g/kgの投与は,汚染された飼料を飼った鳥の抗体位と腸内治癒を高めました.
科学分野:
- 鶏肉科学
- 動物の栄養
- 免疫学
背景:
- ニコラス病 (ND) ワクチン接種はブライラーにとって極めて重要です.
- ミコトキシンに汚染された飼料は,ワクチン接種後の免疫反応と免疫生成を損なう可能性があります.
- アフラトキシンB1 (AFB1) とオクラトキシンA (OTA) は,肉鳥の健康に影響を与える一般的な飼料汚染物質です.
研究 の 目的:
- 菌毒素結合剤が,ブローラー免疫と腸の健康に及ぼすAFB1とOTAの悪影響を軽減する効果を評価する.
- ミコトキシン結合物質が抗体位数とヒト病理学的変化に及ぼす影響を,ミコトキシンに曝露したNDワクチンを接種したニワトリで評価する.
主な方法:
- 20匹の brojler は4つのグループに分けられ,対照群 (基礎飼料),菌毒素被験者 (AFB1 + OTA) と,菌毒素結合剤を1.1g/kgと1.6g/kgで投与した2つのグループに分けられた.
- 鳥は第7日と第21日にNDワクチンを接種した.
- 抗体位数 (血液凝固阻害試験) と,セカル/大腸の組織病理学を特定された日に分析した.
主要な成果:
- 粘膜の破裂,出血,死滅の減少により示された.
- 抗体タイトルの有意な増加は,対照群とより高いミコトキシン結合剤用量 (1. 6 g/ kg) 群で35日目に観察された.
- 1.6 g/kgのミコトキシン・バインダー群は,ミコトキシン・チャレンジ群と比較して,有意に優れた結果を示した.
結論:
- ミコトキシン結合剤の1. 6g/ kgは,AFB1とOTAで挑戦されたNDワクチン接種したブローラーの抗体位を効果的に増加させた.
- ミコトキシン結合剤は,ミコトキシンに汚染された飼料を摂取したニワトリの乳首と大腸の病理学的状態を改善した.
- 食中のミコトキシン結合剤は,ブローカーの健康と免疫機能を維持するのに有益です.
関連する概念動画
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
602
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
602
01:17Drugs for Treatment of Diarrhea-Predominant IBS
1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
820